Your browser doesn't support javascript.
loading
[Analysis of the efficacy and safety of dual immunotherapy in patients with driver gene and programmed death ligand-1 double negative advanced non-small cell lung cancer].
Luan, T; Xie, X H; Lin, X Q; Deng, H Y; Li, Y J; Sun, J L; Yang, G; Zhang, Y H; Wang, S Y; Wang, C C; Zhong, N S; Zhou, C Z.
Afiliación
  • Luan T; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Xie XH; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Lin XQ; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Deng HY; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Li YJ; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Sun JL; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Yang G; Department of Respiratory Medicine, Kunming University of Science and Technology Affiliated Hospital, Yunnan First People's Hospital, Kunming 650000, China.
  • Zhang YH; Department of Respiratory Medicine, Kunming University of Science and Technology Affiliated Hospital, Yunnan First People's Hospital, Kunming 650000, China.
  • Wang SY; Anesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou 310000, China.
  • Wang CC; Anesthesia Surgery Center, Zhejiang Cancer Hospital, Hangzhou 310000, China.
  • Zhong NS; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
  • Zhou CZ; Department of Oncology Medicine, the First Affiliated Hospital of Guangzhou Medical University, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou 510120, China.
Zhonghua Yi Xue Za Zhi ; 104(30): 2797-2804, 2024 Aug 06.
Article en Zh | MEDLINE | ID: mdl-39085146
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Inmunoterapia / Neoplasias Pulmonares Límite: Aged / Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Inmunoterapia / Neoplasias Pulmonares Límite: Aged / Female / Humans / Male / Middle aged Idioma: Zh Revista: Zhonghua Yi Xue Za Zhi Año: 2024 Tipo del documento: Article País de afiliación: China